Most Recent
In the latest ruling on computer-implemented inventions, an IP Australia delegate has shot down fintech Kyro Card's bid to patent a payment system for offering rewards to shoppers, finding the invention was a business scheme implemented on a computer and not a manner of manufacture.
Japanese pharmaceutical company Astellas Pharma has signed a deal worth up to $2 billion with Melbourne-based start-up Audax Biosciences to secure future rights to develop and commercialise its new cancer treatment.
Swiss pharmaceutical company Actelion has brought a fourth patent infringement case over plans to launch a generic version of its blood pressure drug in Australia -- against Lupin unit Generic Health -- after firing off cases against three other drug makers.
Engineering group Sandvik Mining and Construction has prevailed in defence of a patent application for rotary drill technology used for underground mining.
The CSIRO has lost its fight against Israeli ag-tech and biotech company eggXYt’s bid to amend its pending patent application for technology that claims to determine the gender of avian embryos, as the agency continues to oppose the patent's registration.
Indian generics giant Sun Pharmaceutical has offered to grant Ferring Pharmaceuticals a licence to sell a generic version of its IVF drug to win ACCC approval for its $16.7 billion takeover of US-based Organon.
IMB Bank has been hit with a lawsuit by a Perth-based fintech alleging the mutual bank breached the copyright and a licence agreement for its customer relations management software.
Cipla Australia wants an undertaking it intends to give pharma company Actelion over plans to launch a generic version of a blood pressure drug to be shielded from rivals Arrotex, Nova Pharmaceuticals and MSN Laboratories, as those companies battle patent infringement claims.
Arrotex has secured an exclusive licence to sell Sydney-based biotech Recce Pharmaceuticals’ experimental diabetic foot infection treatment in Australia and New Zealand.
The maker of the popular Maxi-Cosi line of child car seats has lost its opposition to a rival's patent for a child car seat designed to reduce the risk of the safety tether breaking in a crash.